SCHEMBL22927229

SCHEMBL22927229

CC(=N)/C=C(/C)Nc1cccc(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
NPC1 O15118 4/20 0.61
RAB9A P51151 4/20 0.61
TP53 P04637 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
MAPK1 P28482 3/20 0.61
HSD17B10 Q99714 2/20 0.61
HTT P42858 3/20 0.58
NPSR1 Q6W5P4 1/20 0.58
ALDH1A1 P00352 4/20 0.56
CYP1A2 P05177 2/20 0.56
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.45
CYP3A4 P08684 2/20 0.44
MMP1 P03956 3/20 0.43
MMP2 P08253 3/20 0.43
MMP9 P14780 3/20 0.43
TSHR P16473 1/20 0.43
NLRP3 Q96P20 2/20 0.42
KDM4E B2RXH2 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7874967 0.80 ALDH1A1 (0.66) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL14536323 0.73 ALDH1A1 (0.53) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL31303335 0.73 HTT (1.00) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL31072411 0.73 HTT (1.00) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL26659454 0.72 PARP1 (0.68) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL26659471 0.72 PARP1 (0.68) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1593329 0.72 KMT2A (0.66) MAPTNPC1RAB9ATP53SMN1; SMN2
Metacetamol SCHEMBL31195432 0.72 ALDH1A1 (1.00) MAPTNPC1RAB9ATP53SMN1; SMN2
Metacetamol SCHEMBL181254 0.72 ALDH1A1 (1.00) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL27704346 0.72 KMT2A (0.55) MAPTNPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230115701-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES UNIV ARIZONA STATE (US) 2023-04-13 US disclosed
US-20210024559-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES UNIV ARIZONA STATE (US) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115701-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES PAICS, DNTT, PNPO MAPT 462/4885NPC1 2399/4885RAB9A 3727/4885
US-20210024559-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES PAICS, DNTT, PNPO MAPT 462/4885NPC1 2399/4885RAB9A 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.